Pay in 4 interest-free payments of $7.12 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Until full safety data are available, cautious patient selection and baseline risk assessment are advised
Back to Journals Journal of Inflammation Research Volume 17 Revolutionizing Treatment Strategies for Autoimmune and Inflammatory Disorders: The Impact of Dipeptidyl-Peptidase 4 Inhibitors Authors Rahim K, Shan M, Ul Haq I, Nawaz MN , Maryam S , Alturki MS, Al Khzem AH , Metwally K, Cavalu S, Alqifari SF , Yahya G Received 18 October 2023 Accepted for publication 9 March 2024 Published 23 March 2024 Volume 2024:17 Pages 18971917 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 2 Editor who approved publication: Dr Adam Bachstetter Kashif Rahim, 1 Muhammad Shan, 2 Ihtisham Ul Haq, 3 5 Muhammad Naveed Nawaz, 2 Sajida Maryam, 3, 4 Mansour S Alturki, 6 Abdulaziz H Al Khzem, 6 Kamel Metwally, 7 Simona Cavalu, 8 Saleh F Alqifari, 9 Galal Yahya 10 1 School of Life Science and Technology, Beijing University of Chemical Technology, Beijing, 100029, Peoples Republic of China
Liraglutide improves vascular dysfunction by regulating a cAMP-independent PKA-AMPK pathway in perivascular adipose tissue in obese mice
Sermorelin This peptide promotes the natural release of growth hormone
These are synthetic peptides used to stimulate the bodys natural production of human growth hormone (HGH)
